The FDA should condition any vaccine approval on open trial data

By December 4, 2020

With only 60 percent of Americans reporting that they’re willing to take a coronavirus vaccine, it’s not enough for the government to simply approve a vaccine candidate. Some Americans are wary of the speed with which these vaccines have been developed; others have doubts about vaccine safety or are skeptical of the medical system. Political interference from the White House in the decision-making process at the Food and Drug Administration has also taken a toll on public trust.

That is why the FDA should condition any vaccine approval on increased transparency on the part of manufacturers. Pharmaceutical companies should be required to release detailed information, including machine-readable data, regarding their vaccine clinical trial designs, implementation and results for scientific scrutiny.

Read the full opinion in the Washington Post.